These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 26668184)

  • 21. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
    Lu VM; Goyal A; Lee A; Jentoft M; Quinones-Hinojosa A; Chaichana KL
    J Neurooncol; 2019 Mar; 142(1):1-10. PubMed ID: 30506498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
    Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
    Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. WHO grade and pathological markers of meningiomas: Clinical and prognostic role.
    Franca RA; Della Monica R; Corvino S; Chiariotti L; Del Basso De Caro M
    Pathol Res Pract; 2023 Mar; 243():154340. PubMed ID: 36738518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
    Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
    Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expression of fatty acid metabolism-associated proteins is correlated with the prognosis of meningiomas.
    Jiang J; Lin C; Liu N; Zhang Z; Sun Y; Fang X; Qi J
    APMIS; 2013 Oct; 121(10):997-1003. PubMed ID: 23879478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression.
    Ke HL; Ke RH; Li ST; Li B; Lu HT; Wang XQ
    J Neurooncol; 2013 Jun; 113(2):327-32. PubMed ID: 23525949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High incidence of TERT mutation in brain tumor cell lines.
    Johanns TM; Fu Y; Kobayashi DK; Mei Y; Dunn IF; Mao DD; Kim AH; Dunn GP
    Brain Tumor Pathol; 2016 Jul; 33(3):222-7. PubMed ID: 26960334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic changes with prognostic value in histologically benign meningiomas.
    Barbera S; San Miguel T; Gil-Benso R; Muñoz-Hidalgo L; Roldan P; Gonzalez-Darder J; Cerda-Nicolas M; Lopez-Gines C
    Clin Neuropathol; 2013; 32(4):311-7. PubMed ID: 23442303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic alterations associated with progression and recurrence in meningiomas.
    Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
    J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The application of flow cytometry for evaluating biological aggressiveness of intracranial meningiomas.
    Lin YW; Tai SH; Huang YH; Chang CC; Juan WS; Chao LC; Wen MJ; Hung YC; Lee EJ
    Cytometry B Clin Cytom; 2015; 88(5):312-9. PubMed ID: 25408130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
    Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
    Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
    Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
    Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.
    Maillo A; Orfao A; Espinosa AB; Sayagués JM; Merino M; Sousa P; Lara M; Tabernero MD
    Neuro Oncol; 2007 Oct; 9(4):438-46. PubMed ID: 17704362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
    Bie L; Zhao G; Ju Y; Zhang B
    Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain invasion assessability in meningiomas is related to meningioma size and grade, and can be improved by extensive sampling of the surgically removed meningioma specimen.
    Pizem J; Velnar T; Prestor B; Mlakar J; Popovic M
    Clin Neuropathol; 2014; 33(5):354-63. PubMed ID: 25034703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.
    Aizer AA; Abedalthagafi M; Bi WL; Horvath MC; Arvold ND; Al-Mefty O; Lee EQ; Nayak L; Rinne ML; Norden AD; Reardon DA; Wen PY; Ligon KL; Ligon AH; Beroukhim R; Dunn IF; Santagata S; Alexander BM
    Neuro Oncol; 2016 Feb; 18(2):269-74. PubMed ID: 26323607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Meningiomas: new prognostic factors].
    Sanz Esponera J
    An R Acad Nac Med (Madr); 2007; 124(2):319-32; discussion 330-2. PubMed ID: 18069599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas.
    Pfisterer WK; Hank NC; Preul MC; Hendricks WP; Pueschel J; Coons SW; Scheck AC
    Neuro Oncol; 2004 Oct; 6(4):290-9. PubMed ID: 15494096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.